Active Ingredient(s): Pralatrexate
FDA Approved: * September 24, 2009
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Folotyn Overview

Pralatrexate (brand name Folotyn) is an anti-cancer therapy.[1] It is the first drug approved as a treatment for patients with relapsed or refractory peripheral T-cell lymphoma, or PTCL[2] — a biologically diverse group of aggressive blood cancers that have a poor prognosis.[2] Contents 1 Approval 2 Mechanism 3 Discovery 4 See also 5 References 6 External links Approval Folotyn was approved by the U.S. Food and Drug Administration (...

Read more Folotyn Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Folotyn Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Injection: 20mg/1ml, 40mg/2ml
  • Solution: 20mg/ml (20mg/ml), 40mg/2ml (20mg/ml)
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Folotyn: (3 results)

Sorted by National Drug Code
  • 48818-001 Folotyn 20 mg/ml Intravenous Injection by Allos Therapeutics
  • 72893-003 Folotyn 20 mg/ml Intravenous Injection by Acrotech Biopharma LLC
  • 72893-005 Folotyn 40 mg/2ml Intravenous Injection by Acrotech Biopharma LLC

Other drugs which contain Pralatrexate or a similar ingredient: (1 result)

Related Folotyn Topics:

Wanting seek out for more information re: Folotyn, my dad will begin using this drug soon and I want to educate myself. ...

Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 28 November 2020.

We are committed to your privacy.

Copyright © 2005-2020 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA